Floating drug delivery: A potential alternative to conventional therapy

International Journal of PharmTech Research

Volumn 2, Issue 1, 2010, Pages 49-59

  Chanda, R ^a   Roy, A ^b   Bahadur, S ^b   Saha, S ^b   Das, S ^c   Choudhury, A ^c  

^a Bengal School of Technology   (India)

^b Department of Pharmaceutical Analysis and Quality Assurance   (India)

^c GRY Institute of Pharmacy   (India)

Author keywords

Buoyancy mechanism; Floating drug; Pharmacokinetic advantages

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMPICILLIN; ATENOLOL; BENSERAZIDE; BICARBONATE; CHITOSAN; CHLORDIAZEPOXIDE; CINNARIZINE; CITRIC ACID; DIAZEPAM; DICLOFENAC; FUROSEMIDE; GRISEOFULVIN; IBUPROFEN; INDOMETACIN; LEVODOPA; MICROSPHERE; MISOPROSTOL; PARACETAMOL; PEPSTATIN; POLYACRYLIC ACID; POLYCARBONATE; POLYMETHACRYLIC ACID; POLYSACCHARIDE; POLYSTYRENE; PREDNISOLONE; TARTARIC ACID; TRANILAST; URSODEOXYCHOLIC ACID;

DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; GASTROINTESTINAL TRACT; HUMAN; HYDROGEL; MIGRATING MYOELECTRIC COMPLEX; MOTOR ACTIVITY; PARTICLE SIZE; PERISTALSIS; PHYSICAL CHEMISTRY; REVIEW; STOMACH EMPTYING;

EID: 77953398197     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Gutierrez-Rocca J, Omidian H, and Shah K. Progresses in Gastroretentive Drug Delivery Systems. Drug Delivery Oral 2003; 23: 152-156
2. Garg S and Sharma S. Gastroretentive Drug Delivery Systems. Drug Delivery Oral 2003; 20: 160-166
3. Hwang SJ, Park H, and Park K. Gastroretentive Drug Delivery Systems. Critical reviews in therapeutic drug delivery system 1998; 15(3): 243-284
4. Desai S, and Bolton S. A floating controlled release drug delivery system: In vitro-In vivo evaluation. Pharmaceutical Research 1993; 10(9): 1321-1325.
5. Whitehead L, Fell JT, and Colleh JH. Development of a Gastroretentive Dosage Form. Euro. J. Pharma. Sci. 1996; 4(1):182-185
6. st Edition 2005; pp. 335-338.
7. Willison CG, Washington N, and Greaves JL. Stomach and Overview. Int. J. Pharm. 1989; 50: 55-65
8. Timmermans J, and Moes AJ. How Well Do Floating Dosage Forms Float? Int. J. Pharm. 1990; 62(3): 207-216
9. Koner P, Saudagar RB, and Daharwal SJ. Gastroretentive drugs-A novel approach towards floating therapy. Pharmainfo.net. 2007; 11: 15-23
10. Eytan A, Lavyb KE, Friedmana M, and Hoffmana A. Expandable Gastroretentive Dosage forms. J Controlled Release 2003; 90: 143-162
11. Rubinstein A, and Friend DR. Specific delivery to the gastrointestinal tract. In: Polymeric Site Specific Pharmaco Therapy., A.J Domb (Ed)., Wiley Chichester, New York,1994, pp. 282-283.
12. Singh BN, and Kim KH. Floating drug delivery systems: an approach to oral Controlled Drug delivery via gastric retention. J Controlled Release 2000; 63(1-2): 235-259
13. Timmermans J, Gansbeke BV, and Moes AJ. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Proc. 5th Int. Conf. Pharm. Technol. 1989; I: 42-51
14. Chickering DE, Jacob JS, and Mathowitz E. Bioadhesive microspheres II: Characterization and evaluation of bioadhesion involving hard, bioerodible polymers and soft tissue. Reactive Polymers 1995; 25:189-206.
15. Bardonet PL, Faivre V, Pugh WJ, and Piffaretti JC. Gastro retentive dosages form. J Controlled Release 2006; 111: 1-18
16. Cargill R. Controlled gastric emptying, effects of physical properties on gastric residence times of non disintegrating geometric shapes in beagle dogs. Pharm. Res. 1988; 5(8): 533-536
17. Oth M, Franz M, and Timmermans J. The Bilayer Floating Capsule: A Stomach-Related Drug Delivery System for Misoprostil. Pharm. Res. 1992; 9: 298-302
18. Khosla R, and Davis SS. The Effect of Tablet Size on the Gastric Emptying of Non-Disintegrating Tablets. Int. J. Pharm. 1990; 62(2-3): R9-R11
19. Munk J. Direct Measurement of Pyloric Diameter and Tone in Man and Their Response to Cholecystokinin. In: Gastrointestinal Motility in Health and Disease, Duthie H.L (Ed)., MTP Press, Lancaster,1978, pp. 349-359
20. Li S. Effect of HPMC and Carbopol on the Release and Floating Properties on Gastric Floating Drug Delivery System Using Factorial Design. Int. J. Pharm. 2003; 253(1):13-22
21. Chien YW. Oral Drug Delivery Systems. In: Novel Drug Delivery Systems, Chien YW (Ed)., Marcel Dekker, New York, 1992, pp.139-196
22. Muller-Lissner SA. A Floating Capsule with Slow Release of Drugs: a New Method of Oral Drug Medication. Dtsch.Med.Wochenschr. 1981; 106: 1143-1147
23. Whitehead L. Floating Dosage Forms: An In Vivo Study Demonstrating Prolonged Gastric Retention. J Controlled Release 1998; 55(1): 3-12
24. Mojaverian P. Effect of Gender, Posture, and Age on Gastric Residence Time of an Indigestible Solid: Pharmaceutical Considerations. Pharm. Res. 1988; 5(10): 639-644
25. Timmermans J, and Moes AJ. Factors Controlling the Buoyancy and Gastric Retention Capabilities of Floating Matrix Capsules: New Data for Reconsidering the Controversy. J. Pharm. Sci. 1994; 83(1):18-24
26. Fabregasl JL. In Vitro Testing of an Antacid Formulation with a Prolonged Gastric Residence Time. Drug Dev. Ind. Pharm. 1994; 20: 1199-1212
27. El-Gibaly I. Development and In Vitro Evaluation of Novel Floating Chitosan Microcapsules for Oral Use: Comparison with Non-Floating Chitosan Microspheres. Int. J. Pharm. 2002; 249(1): 7-21
28. Stithit S, and Chien W, Price JC. Development and Characterization of Buoyant Theophylline Microsperes with Near Zero-Order Release Kinetics. J. Microencap. 1998; 15: 725-737
29. He P, Davis SS, and Illum L. Sustained-Release Chitosan Microspheres Prepared by Novel Spray Drying Methods. J. Microencap. 1999, 16(2): 343-355
30. Timmermans J, and Moes AJ. Measuring the Resulting Weight of an Immersed Test Material II: Examples of Kinetic Determinations Applied for Monolithic Dosage Forms. Acta Pharm. Technol. 1990, 36(1): 176-180
31. Sangekar S. Evaluation of Effect of Food and Specific Gravity on Tablets on Gastric Retention Time. Int. J. Pharm. 1987; 35(3): 187-191
32. Cromer AH. Physics for the Life Sciences. McGraw-Hill Intern Book Co., Tokyo, 1981, pp.134-153
33. Menon A, Ritschel WA, and Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J. Pharm. Sci. 1994; 83: 239-245
34. Ritschel WA, Menon A, and Sakr A, Biopharmaceutic evaluation of furosemide as a potential candidate for a modified release peroral dosage form, Methods Find., Exp. Clin. pharmacol. 1991, 13: 629-636
35. Ichikawa M, Kato T, Kawahara M, Watanabe S, and Kayano M. A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs. J. Pharm. Sci. 1991; 80: 1153-1156
36. Rouge N, Buri P, and Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 1996; 136: 117-139
37. Kopitar Z, Vrhovac B, Povsic L, Plavsic F, Francetic I, and Urbancic J. The effect of food and metoclopramide and side effects of bromocriptine. Eur. J. Drug Metab. Pharmacokinet. 1991; 16:177-181
38. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102: 720-727
39. Katayama H, Nishimura T, Ochi S, Tsuruta Y, and Yamazaki Y. Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pylori. Biol. Pharm. Bull. 1999; 22: 55-60
40. Chitnis VS, Malshe VS, and Lalla JK. Bioadhesive polymers- synthesis, evaluation and application in controlled release tablets. Drug Dev. Ind. Pharm. 1991; 17: 879-892.